Constitutive active/androstane receptor (CAR), a member of the nuclear steroid/thyroid hormone receptor family, activates transcription of numerous hepatic genes upon exposure to therapeutic drugs and environmental pollutants. Sequestered in the cytoplasm, this receptor signals xenobiotic exposure, such as phenobarbital (PB), by translocating into the nucleus. Unlike other hormone receptors, translocation can be triggered indirectly without binding to xenobiotics. We have now identified a membrane-associated subunit of protein phosphatase 1 (PPP1R16A, or abbreviated as R16A) as a novel CAR-binding protein. When CAR and R16A are coexpressed in mouse liver, CAR translocates into the nucleus. Close association of R16A and CAR molecule on liver membrane was shown by fluorescence resonance energy transfer (FRET) analysis using expressed yellow fluorescent protein (YFP)-CAR and CFP-R16A fusion proteins. R16A can form dimer through its middle region, where protein kinase A phosphorylation sites are recently identified. Translocation of CAR by R16A correlates with the ability of R16A to form an intermolecular interaction via the middle region. Moreover, this interaction is enhanced by PB treatment in mouse liver. R16A specifically interacted with PP1␤ in HepG2 cells despite the highly conserved structure of PP1 family molecules. PP1␤ activity was inhibited by R16A in vitro and coexpression of PP1␤ in liver can prevent YFP-CAR translocation into mouse liver. Taken together, R16A at the membrane may mediate the PB signal to initiate CAR nuclear translocation, through a mechanism including its dimerization and inhibition of PP1␤ activity, providing a novel model for the translocation of nuclear receptors in which direct interaction of ligands and the receptors may not be crucial.
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Phenobarbital (PB), a sedative, represents a myriad of therapeutic drugs and environmental chemicals that induce xenobiotic-metabolizing enzymes, such as cytochromes P450. CAR was first identified as a PB-activated receptor mediating the induction of the CYP2B genes (Honkakoski et al., 1998; Sueyoshi et al., 1999; Wei et al., 2000) . This receptor is now known to be activated, not only by a myriad of xenobiotics but also endobiotics such as estrogens (Kawamoto et al., 2000) and is implicated in the regulation of numerous hepatic genes in xenobiotic, endobiotic, and energy metabolism (Ueda et al., 2002; Kakizaki et al., 2003; Rosenfeld et al., 2003; Kodama et al., 2004; Tien and Negishi, 2006) . Furthermore, animal model studies using CAR-null mice revealed that the receptor is an essential factor in chemical promotion of genotoxic carcinogen-induced hepatocellular carcinoma Huang et al., 2005) and contributes in pathogenesis of nonalcoholic steatohepatitis (Yamazaki et al., 2007) . Although it has become evident that CAR plays an important role in regulating various hepatic functions (Honkakoski et al., 2003; Qatanani and Moore, 2005; Tien et al., 2007) , the molecular mechanism of CAR activation is not yet well understood (Swales and Negishi, 2004; Timsit and Negishi, 2007) . Activation seems to begin with the nuclear translocation of CAR, because the receptor, which is retained in the cytoplasm of liver cells, accumulates in the nucleus after treatment with activators such as PB . Observations from an experiment directly expressing CAR in mouse livers revealed that CAR contains a LXXLXXL motif (also called Xenobiotic Response Signal) near the C terminus of the molecule that confers xenobiotic responsiveness to the receptor (Zelko et al., 2001) . Moreover, the nuclear translocation of CAR occurs in the absence of the ligand-dependent activation function 2. This observation suggests that CAR does not require direct binding of activators for translocation, consistent with the fact that PB and other CAR activators showed no direct binding to the receptor.
Signal transduction is proposed as an alternative mechanism regulating CAR nuclear translocation, because okadaic acid repressed the nuclear accumulation of CAR in PBtreated mouse primary hepatocytes, suggesting the involvement of protein phosphatases Yoshinari et al., 2003) . CAR forms a protein complex with the 90-kDa heat shock protein and cytoplasmic CAR retention protein in cytoplasm, and PP2A is recruited upon activation by PB Yoshinari et al., 2003) . To retain CAR in cytoplasm, a signaling pathway including extracellular signal-regulated kinase 1/2 plays an important role (Koike et al., 2007) . Furthermore, Ser202 dephosphorylation was reported to be required for mouse CAR translocation into the nucleus (Hosseinpour et al., 2006) . In this context, the elucidation of how xenobiotics transmit the signal triggering CAR nuclear translocation is of the highest priority. Using yeast two-hybrid screening, we identified proteins that bound to CAR and found a member of the family of regulatory subunits for serine/threonine protein phosphatase 1 (PPP1R16A or abbreviated as R16A). This mouse protein was originally reported as an interacting protein of PP1 in yeast two-hybrid screening and named MYPT3 (Skinner and Saltiel, 2001 ) based on its homology with members of the myosin phosphatase targeting subunit (MYPT) family. Although liver is one of multiple mouse tissues that express R16A, hepatic function of R16A is not known.
Here, we first characterized R16A as a membrane-associated protein. Because transformed cells, including HepG2 cells, which are generally used to investigate the translocation mechanism, lack the proper regulation of CAR translocation, fluorescent resonance energy transfer (FRET) and mammalian two hybrid assays were performed directly in mouse livers to investigate the role of R16A in the nuclear translocation of CAR. We here present the experimental consideration that PB elicits signal transduction at the membrane to initiate the translocation of CAR to the nucleus.
Materials and Methods
Animals. Cr1:CD-1(ICR)BR male mice were purchased from Charles River Laboratories, Inc. (Wilmington, MA). For drug treatment, PB (100 mg/kg) was administered i.p. All animal procedures were approved by the Animal Ethics Committee of National Institute of Environmental Health Sciences.
Yeast Two-Hybrid Screening. Matchmaker Gal4 two-hybrid system cDNA library from mouse liver (Clontech, Mountain View, CA) was screened using hCAR L342A/pAS2-1 as bait. We chose to use this mutant as bait for the following reasons: 1, the equivalent mutation in mouse CAR, L352A, abolishes its constitutive transactivation activity (Choi et al., 1997) ; 2, In its reported three-dimensional structure, the hCAR ligand binding domain formed a complex with RXR and the SRC-1 peptide (Xu et al., 2004) , Leu342 exists near the SRC-1 peptide. Based on 1 and 2, we anticipated that the hCAR L342A mutant would have less affinity with the SRC-1 type coactivators. Thus using this mutant may provide less of a chance to reclone coactivators already reported by others in our yeast two-hybrid screening. Four of a total of 53 positive clones from 1.6 ϫ 10 7 primary transformants matched in sequence with MYPT3/PPP1R16A (Skinner and Saltiel, 2001 ) (Gene Bank accession number NM_033371).
Plasmids and Antibodies. The plasmids hCAR/pEYFP-c1, hCAR/ pECFP-c1 and (NR1) 5 pGL3-tk were described previously Zelko et al., 2001 ). The following newly constructed plasmids were used in this report. R16A full-length coding cDNA cloned into pCDNA3.1/V5-His TOPO (Invitrogen, Carlsbad, CA); pEYFP-c1 and pECFP-c1 (Clontech); pBind and pAct (Promega, Madison, WI); and pNTAP-B (Stratagene, La Jolla, CA). Human PP1␤ cDNA cloned into pGEX4T-3 (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK); pECFP-c1. Human CAR cDNA cloned into pGEX4T-3. All deletion mutants and site directed mutants were constructed using QuikChange site-directed mutagenesis kit (Stratagene) with proper primers. To produce the R16A antiserum, bacterially expressed GST-R16A fusion protein was purified by glutathione-Sepharose (GE Healthcare) and was injected to immunize rabbits. The other antibodies used in this article were: anti-caveolin (BD Transduction Laboratories, San Jose, CA,), anti-tubulin ␣ (Santa Cruz Biotechnology, Santa Cruz, CA), anti-lamin ␤ (Santa Cruz), PP1␣ (Santa Cruz), anti-PP1␤ (Santa Cruz), and anti-PP1␥ (Santa Cruz).
GST Pull-Down Assay. R16A protein was expressed using the TNT-coupled reticulocyte lysate system (Promega) and pcDNA3.1/ R16A. The in vitro-translated 35 S-labeled R16A was incubated with GST-hCAR-fusion protein on a glutathione resin at room temperature for 30 min. The resin was washed four times with HEPESNaOH buffer, pH 7.6, 0.1 M NaCl, 0.1% Triton X-100, and the 35 S-labeled R16A bound to the resin was separated on a NuPAGE Novex 4-12% Bis-Tris Gel (Invitrogen) and detected by autoradiography .
Immunohistochemistry. Frozen mouse liver sections were subjected to immunofluorescent staining using anti-R16A serum (1:100 dilution) and Alexa Fluor 555 goat anti-rabbit IgG (Invitrogen). Fluorescent images of the sections were captured with a confocal Zeiss LSM 510 microscope. Nuclei in the liver sections were stained with Hoechst S33258.
Cell Fractionation and Western Blot. Mouse livers were homogenized in 10 mM HEPES-NaOH buffer, pH 7.6, containing 0.25 M sucrose and complete protease inhibitor cocktail (Roche). The cell membrane fraction was prepared as previously reported (Koike et al., 2005) . For cytosolic fraction, the 100,000g supernatant of liver homogenates was used. The nuclear extract was prepared as previously reported (Gorski et al., 1986; Honkakoski et al., 1998) . For Western blot analysis, proteins were separated on a NuPAGE Novex 4-12% Bis-Tris Gel, and the R16A protein on the PVDF membrane was detected with rabbit anti-R16A serum.
Expression of Fluorescent Protein-Tagged Protein in Liver and Acceptor Photobleaching FRET Analysis. Using the tail vein injection method (Zelko et al., 2001; Sueyoshi et al., 2002) , protein was expressed in mouse liver for 8 h with or without PB treatment. Liver frozen sections were prepared, and expressed yellow fluorescent (YFP) and cyan fluorescent (CFP) fusion proteins were visualized under a confocal Zeiss LSM510 microscopy system (Carl Zeiss, Thornwood, NY). For acceptor photobleaching FRET analysis, excited signals (at 458 nm) from 5 m confocal slices were captured twice before and twice after YFP photobleaching (25 pulses of laser at 514 nm) with a 40ϫ oil immersion objective (1.3 numeric aperture). Emissions of CFP and YFP were collected simultaneously using a META spectral detector (Zeiss) in the range of 450 to 540 nm (Squires et al., 2004) . Subsequently, the YFP and CFP emisions were extracted via linear unmixing using software provided by Zeiss. Dequenching of CFP was quantified for multiple liver cells, and FRET efficiency E was calculated with the equation E ϭ 1 Ϫ (Ii/Ii 0 ), where Ii is fluorescence intensity before the bleaching and Ii 0 is that after the bleaching (Harpur and Bastianens, 2001) . Distances between CFP and YFP were estimated from this efficiency E and equation E ϭ R 0 6 /(R 0 6 ϩ R 6 ), where R (nanometers) is the actual distance between the centers of the fluorophores and R 0 (nanometers) is the distance at which energy transfer efficiency E is 50%. R 0 was reported to be 4.9 nm for CFP donor and YFP acceptor combination (Harpur and Bastianens, 2001) . A conventional fluorescent microscope (Axioplan; Zeiss, Welwyn Garden City, UK) equipped with specific filter sets for CFP and YFP was employed for counting cell numbers showing differential distribution of YFP-tagged CAR by coexpression of CFP-tagged R16A and its deletion mutants as described in the previous report (Hosseinpour et al., 2006) .
Coprecipitation of R16A and PP1␤. R16A tagged with tandem affinity peptides was expressed in HepG2 cells plated on 10-cm dish by transfecting the cells with R16A cloned into pNTAP-B (24 g) using Lipofectamine 2000 (Invitrogen). R16A protein was purified with streptavidin resin (Stratagene) according to the manufacturer's protocol and separated on a SDS-PAGE gel. Two major bands stained with Colloidal Blue Staining Kit (Invitrogen) were subjected to mass spectrometric analysis. Gel bands were excised manually and digested with trypsin (Promega) for 8 h in an automated fashion with a Progest In-gel Digester from Genomics Solutions. Samples were lyophilized to dryness and resuspended in 50:50 (v/v) 0.2% formic acid: acetonitrile. Samples (0.3 l) were then spotted onto a 192-sample stainless steel MALDI plate and mixed on target with 0.3 l of 33% saturated ␣-cyano-hydroxycinnamic acid. Mass spectrometry (MS) and tandem mass spectrometry (MS/MS) were then performed with the use of an Applied Biosystems 4700 Proteomics Analyzer in the positive ion and reflector modes. The MS was calibrated internally using autolytic tryptic peptides, and the MS/MS was calibrated externally using the fragment ions of the angiotensin I MϩH ion (m/z 1296.68). A focus mass of m/z 2000 was used for the MS acquisition. For the MS/MS, 1000 V was used for the collision energy, and argon was used as the collision gas with a recharge threshold set at 1.0 ϫ 10 Ϫ7 torr. Protein identification was then performed by interrogating both MS and MS/MS using the MASCOT search engine and the entire NCBI nonredundant database. Search parameters included an allowance of two missed tryptic cleavages, a 0.06-Da mass tolerance for the MS data, a 0.1-Da mass tolerance for the MS/MS data, and an allowance for variable oxidation of methionine residues. Western blotting for the same purified materials was performed using anti-PP1␣, anti-PP1␤, and anti-PP1␥ from Santa-Cruz.
Mammalian Two-Hybrid Assay. CheckMate Mammalian TwoHybrid System (Promega) was used. HepG2 cells were transfected with pG5-Luc, R16A in pBind, and R16A and its deletion mutants in pAct. After 48 h of incubation, firefly luciferase activities from pG5-Luc reporter normalized against Renilla reniformis luciferase activities of pBind were determined using the Dual-Luciferase Assay System (Promega, Madison, WI). The same sets of the plasmids were injected via the tail vein using TransIt In Vivo Gene Delivery System (Mirus, Madison, WI). Liver homogenates were prepared in Passive Lysis Buffer (Promega) at 16 h after the DNA injection and luciferase activity was determined.
Phosphatase assay. Protein phosphatase activities of GST-PP1␤ were assayed using the Protein Serine/Threonine Phosphatase Assay System (New England Biolabs, Ipswich, MA) by following the manufacturer's protocol. Each reaction mixture contains 5 l of PP1␤ on the resin and varying amounts of R16A and 10 M myelin basic protein phosphorylated by PKA and [ 32 P]ATP. After 20-min incubation at 30°C, radioactivity in trichloroacetic acid-soluble supernatant was measured by scintillation counting.
Results

PPP1R16A Interaction with CAR.
Yeast two-hybrid screening of a mouse liver cDNA library using human CAR L342A mutant as bait gave us four positive clones along with many RXR␣, RXR␤, and corepressors clones. The deduced amino acid sequences of the four positive clones were identical to the previously reported MYPT3, a regulatory subunit of PP1 (Skinner and Saltiel, 2001 ). MYPT3 has now been classified as PPP1R16A in the mouse genome nomenclature and Entrez Gene database at NCBI (Ceulemans et al., 2002; Cohen, 2002) . Hereafter R16A, an abbreviated name of PPP1R16A, will be used. The R16A molecule contains a potential prenylation site at the C terminus, thus indicating that R16A may be a membrane-anchoring protein.
In fact, our immunofluorescent staining analysis of liver sections using anti-R16A antibody showed that R16A localized with the cell membrane in mouse livers (Fig. 1A) . In Western blot analysis using anti-R16A antibody (Fig. 1B) , a band with 70 kDa was detected only in membrane extracted fractions but not in cytosolic or in nuclear extract fractions with or without PB treatment. A GST pull-down assay confirmed that in vitro synthesized R16A bound to GST-CAR but not to GST (Fig. 1C) . Thus, R16A is a cell membrane-anchoring/targeting subunit of PP1 that can bind to CAR.
R16A Induced CAR Nuclear Translocation. When expressed alone in mouse livers in vivo, CFP-CAR was primarily localized in the cytoplasm and accumulated into the nucleus only after PB induction ( Fig. 2A ) as previously reported (Zelko et al., 2001; Wang et al., 2004; Xia and Kemper, 2005; Hosseinpour et al., 2006) . By injecting expression plasmids via the tail vein, YFP-tagged R16A and CFP-tagged CAR were coexpressed in mouse livers (Fig. 2B) . As expected, YFP-R16A was localized to the cell membrane in a similar manner to that observed in Fig. 1A by R16A antiserum. It is noteworthy that cells coexpressing R16A and CAR displayed Fig. 1 . Membrane localization of R16A and its binding to CAR. A, immunofluorescent staining shows cell membrane localization of R16A. Fluorescence of secondary antibody reacting Anti-R16A and that of nuclear staining was shown in yellow and blue, respectively. B, Western blot detects R16A only in cell membrane fraction. Liver membrane (10 g/ lane), cytosolic (100 g/lane), and NE (10 g/lane) fractions were prepared from PB-treated (100 mg/kg for 3 h), and nontreated mice were applied on an SDS polyacrylamide gel, transferred, and stained with anti-R16A antibody. C, GST pull-down assay. The input lane contains 16.7% of GST fusion protein used for pull-down assays.
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R16A Closely Associated with CAR on Liver Membrane. Given the fact that R16A can interact with CAR in yeast cells and the GST pull-down analysis results in Fig. 1C , CAR and R16A may be interacting in the liver in vivo at the colocalization sites on the cell membranes observed in Fig.  2B . To examine this interaction, acceptor photobleaching FRET analysis was performed between YFP-R16A and CFP-CAR using liver cells expressing these two proteins. As illustrated in Fig. 2C , when CFP molecule is excited by a laser at 458 nm, both CFP and YFP fluoresce if these two molecules are close enough to each other so that FRET from CFP to YFP occurs. CFP emission is partially quenched because a part of its excited energy is used to produce YFP emission. After photobleaching YFP (the FRET acceptor molecule in this experimental set up) using 514 nm laser, CFP emission becomes stronger (donor dequenching effect), because there is no energy transfer between the donor and acceptor molecules. The proteins were visualized before and after photobleaching of YFP fusion protein in the area shown with a red square in Figs. 2C and a magnified image of this area was shown in Fig. 2D . The intensity of the CFP-CAR fluorescence in randomly selected areas on the cell membrane (Fig. 2D , area 1-3) increased concomitantly with the decrease of that from YFP-R16A. Quantitative analysis of the CFP-CAR dequenching by YFP-R16A photobleaching was shown in Fig.  2D , bottom. In comparison, CFP-CAR intensity localized in the nuclei was not changed by photobleaching (Fig. 2D, area  4) . Similar analysis of YFP and CFP fluorescent intensity on the membranes of more than 10 cells revealed that the FRET efficiency between YFP-16A and CFP-CAR was 61 Ϯ 11%.
FRET efficiency E was calculated with the equation E ϭ 1 Ϫ (Ii/Ii 0 ), where Ii is CFP-CAR fluorescence intensity before the bleaching of YFP-R16A and Ii 0 is that of after the bleaching (Harpur and Bastianens, 2001) . Using a R 0 ϭ 4.9 nm, the distance at which energy transfer efficiency is 50% in ideal conditions for CFP donor and YFP acceptor (Harpur and Bastianens, 2001) , the distance between the two tags was estimated to be 4.6 Ϯ 0.36 nm. This distance can be even smaller given the fact that FRET can be less effective depending on the orientations of dipoles and the environment of the fluorescent dyes. Although the results do not establish the direct interaction of the two molecules, the results are consistent with the hypothesis that R16A and CAR are directly interacting on the membrane, considering that their estimated radii from molecular weight of these proteins using the equation for globular proteins, r ϭ 6.76 ϫ 10 Ϫ2 MW 1/3 , are 2.3 and 2.6 nm, respectively. Dimerization of R16A and CAR Nuclear Translocation. Acceptor photobleaching FRET analysis was applied for YFP-R16A and CFP-R16A coexpressed in mouse liver. YFP-R16A molecule in the area shown with red square was photobleached as in Fig. 3A and a magnified image of the area was shown in Fig. 3B . The intensity of the CFP-R16A fluorescent in randomly selected areas on the cell membrane (Fig. 3B, area 1-4) increased concomitantly with the decrease of that from YFP-R16A. Although relative fluorescence intensities differed in these areas, all areas randomly chosen showed that the intensity of CFP-R16A fluorescence increased as that of YFP-R16A decreased after photobleaching. The similar analysis, using more than 10 liver cells determined, that the FRET efficiency between YFP-16A and CFP-R16A was 31 Ϯ 7% and suggested that two tags connected with R16A molecules were present within an estimated distance of 5.6 Ϯ 0.32 nm, thus indicating the intermolecular interaction of R16A on the cell membrane. A mammalian two-hybrid assay was performed to obtain additional evidence supporting the direct interaction of R16A molecules and to delineate a region of the molecule responsible for this interaction. Luciferase activity from a Gal4 binding site driven reporter was increased when pBind-R16A and pAct-R16A were coexpressed in HepG2 cells (Fig. 4A) . The coexpression of the C-terminal subdomain (R16A304-524), but not the N-terminal subdomain (R16A1-303), increased luciferase activity. These results suggest that the C-terminal fragment can mediate the intermolecular interaction of R16A. Subsequently, three deletion mutants within the Cterminal fragment were generated to delineate the region responsible for the intermolecular interaction: R16A⌬304-513, R16A⌬304-403, and R16A⌬404-513 (Fig. 4A) . In the mammalian two-hybrid assay, R16A⌬403-513 strongly interacted with R16A, although the degree of the interaction was approximately 60% of the R16A-R16A interaction, whereas R16A⌬304-403 exhibited a weak interaction with R16A and R16A⌬304-513 showed no interaction. Thus, the Next, we examined whether a correlation existed between the CAR translocation capability and intermolecular interaction of R16A. YFP-tagged CAR was directly expressed in mouse livers together with CFP tagged R16A, R16A1-303, R16A304-524, R16A⌬304-513, R16A⌬304-403, or R16A⌬404-513 to analyze its intracellular localization (Fig. 4B) . Of more than 100 cells counted, 80% retained CAR in the cytoplasm if it was expressed alone. When CAR was coexpressed with R16A, 70% of cells predominantly localized CAR in the nucleus, and another 10% showed CAR localized equally in the nucleus and cytoplasm. The coexpression of the R16A303-524 greatly increased the number of cells localizing CAR to the nucleus, whereas that number was not increased when the R16A1-303 was coexpressed. With respect to deletion mutants, R16A⌬304-513 did not alter the cytoplasmic localization of CAR. In the case of R16A⌬304-403, a slight decrease of cytoplasmic CAR localization inversely correlated with a similar increase of the receptor in the nucleus, suggesting the weak ability of R16A⌬304-403 to nuclear translocate CAR. The strongest CAR nuclear translocation activity was observed with R16A⌬404-513 (Fig. 4B) ; nearly 40% decrease in cytosolic localization was replaced by a 30% increase in predominantly nuclear localization. The order of strength of R16A and its deletion mutants in translocation of CAR into the nucleus was: R16A ϭ R16A304-524 Ͼ R16A⌬404-513 Ͼ Ͼ R16A⌬304-403 Ͼ 16A⌬304-513 ϭ R16A1-303. This order was identical to the strength of the intermolecular interaction of R16A and its mutants as seen in mammalian twohybrid assay, thus correlating the interaction with the CAR nuclear translocation in mouse livers.
If, in fact, R16A regulates xenobiotic-induced nuclear translocation of CAR, R16A should be able to form the interaction in response to xenobiotics. To obtain evidence for PB-elicited interaction of R16A, a mammalian two-hybrid assay was performed in mouse livers, in which pBind-R16A and pAct-R16A were coinjected into mice via the tail vein and the mice were treated with PB. The livers were removed, homogenized, and subjected to luciferase assay. PB treatment increased luciferase activity by 3-fold, indicating that it enhanced the interaction of R16A molecules (Fig. 5) . Likewise, R16A304-524 also increased the interaction with R16A after PB treatment. In contrast, when pBind-R16A⌬304-513, which lacks the region responsible for the interaction, was coinjected with pAct-R16A, PB treatment did not enhance their interaction. In a control experiment, R16A showed no interaction with Gal4 DBD and VP16 activation domain, either before or after PB treatment. In non-PB-treated animals, pBind-R16A and pAct-R16 cotransfection gave 1.5-to 2.0-fold higher reporter activity than that of the two negative controls using R16A expression vectors and empty vectors. The weak basal R16A dimerization in mouse liver nuclei is consistent with the R16A dimerization on the liver cell Fig. 4 . Intermolecular interaction potency of R16A molecules correlates with potency for CAR nuclear localization. A, R16A intermolecular interaction shown by mammalian two-hybrid assays. The assay was performed using wild-type R16A and various deletion mutants as described under Materials and Methods. cDNA encoding a full-length R16A was cloned into pBind, for expression of Gal4 DBD-R16A fusion protein. R16A and deletion mutants were cloned into pAct, for expression of VP16 AD fusion proteins. DBD and AD indicate empty pBind and pAct vectors. Bars indicate the standard deviation from triplicate measurements. B, YFP-hCAR localization in liver cells coexpressing CFP-R16A and its deletion mutants. YFP-hCAR was coexpressed with CFP-R16A or each of the deletion mutants in mouse livers. Top bar shows YFP-hCAR localization without any coexpression. Intracellular localization was categorized into three groups: nuclear localization (N), cytoplasmic localization (C), similar localization in both nucleus and cytoplasm (N ϭ C). Approximately 120 cells were randomly selected for each group to analyze the localizations. Schematic representation of R16A and deletion mutants coexpressed with YFP-hCAR are shown on the left side of the categorized data. Fig. 5 . PB-elicited intermolecular interaction of R16A in mouse liver. Mammalian two-hybrid assay showing increased interaction of R16A in mouse liver after treatment with PB. Plasmids were injected via the tail vein, and mice were treated with PB as described under Materials and Methods. DBD and AD represent pBind and pAct used as controls, respectively. Bars indicate means with standard deviation from quadruplicate measurements.
membrane observed by FRET analysis in Fig. 3 . The degree of interactions detected by these two methods can not be directly compared because of the very different nature of these two methods. The results indicate that PB can increase the interaction of R16A molecules in mouse liver.
Specific Interaction between R16A and PP1␤. Because R16A was originally reported as a PP1-interacting protein (Skinner and Saltiel, 2001 ), R16A and PP1 interaction was examined in HepG2 cells. Tandem affinity purification (TAP) tagged R16A was expressed in HepG2 cells and precipitated with streptavidin resin. Then the precipitated materials were separated on an SDS-PAGE gel, and two major proteins were detected by Coomassie Brilliant Blue staining. Mass spectrometry analysis identified the two bands as R16A and human PP1␤ catalytic subunit (data not shown). Because there are highly homologous subtypes of PP1 catalytic subunit in HepG2 cells, we analyzed the same samples further using specific antibodies against PP1 subtypes. TAP-R16A was shown to be efficiently precipitated by streptavidin resin as detected by Western blotting using anti-R16A serum (Fig. 6A) . In crude extracts, in addition to ectopically expressed TAP-tagged R16A, human R16A in HepG2 cells were detected by our antibody. Endogenous R16A was copurified, possibly because of dimer formation of R16A molecules, in the eluent from streptavidin resin. Using anti PP1 antibodies, only PP1␤-specific antibody detected a band in streptavidin resin purified fraction, whereas anti-PP1␣ or anti-PP1␥ antibodies did not. The results overall established specific interaction of PP1␤ and R16A. Next we analyzed PP1␤ activity modulation by R16A. PP1␤ activity was effectively inhibited (more than 60%) by R16A protein expressed in bacteria as GST fusion protein (Fig. 6B) . We also analyzed the inhibition by mutant R16A (F67A and F69A double mutation), which has a mutated PP1 interaction consensus sequence identified in a previous report (Skinner and Saltiel, 2001 ). The mutant was around 30% less effective at inhibiting PP1␤, suggesting existence of secondary interaction sites in R16A for PP1␤ inhibition. In contrast with these fusion proteins, GST alone had no effect on the protein phosphatase activity.
PP1␤ Inhibited CAR Translocation by PB.
To analyze PP1␤ effect on PB-induced CAR nuclear translocation, CFPtagged PP1␤ was coexpressed in liver cells with YFP-tagged CAR, and the CAR localization change by PB was analyzed. As reported previously (Zelko et al., 2001; Hosseinpour et al., 2006) , without PB, less than 20% of the cells show exclusively nuclear YFP-hCAR localization, and PB treatment increased this value to nearly 70%. Active PP1␤ coexpression increased CAR nuclear localization slightly without drug treatment. With PB, however, YFP-hCAR translocation into nucleus was strongly inhibited by the coexpression (Fig. 7A ). In contrast, mutated PP1␤, in which the active center histidine was replaced by alanine (PP1␤ H124A ), has no effect on translocation. To evaluate the effect of PP1␤ inhibition of CAR nuclear translocation against the receptor's transactivation activity, we next examined CAR activity in the liver using a NR1 reporter gene (Fig. 7B) . The NR1 reporter has been well established to be activated by CAR Sueyoshi et al., 1999) . Mouse livers were transfected with (NR1) 5 pGL3-tk reporter with PP1␤ or its active site mutant. The reporter was activated by PB at approximately 3.5-fold. This activation was strongly inhibited by active PP1␤ coexpression, and the no PB activation was observed. Meanwhile, PP1␤ active site mutant H124A showed no effect on reporter activation by PB treatment. Thus, these results were consistent with PP1␤'s effect on CAR translocation.
Discussion
In this article, the role of R16A, a membrane-anchored subunit of PP1, in regulating CAR nuclear translocation was investigated in mouse liver. Direct interaction between R16A and CAR was suggested by in vitro and in vivo experiments including FRET analysis in liver cells. R16A coexpression induced CAR translocation into the nucleus. R16A seems to be capable of forming intermolecular interaction in response to PB, and potency for the dimer/oligomer formation and Fig. 6 . R16A specifically interacts with PP1␤. A, tandem affinity tagged R16A (TAP-R16A) was expressed in HepG2 cells by transfecting the cells with R16A/pNTAP-B plasmid. Tagged R16A was purified by Streptavidin resin as under Materials and Methods. Crude and purified materials were separated on a SDS-PAGE gel and Western blotting was performed with anti-R16A, anti-PP1␤, anti-PP1␣, and anti-PP1␥ antibodies. B, R16A inhibition of PP1␤ activity. PP1␤ activities were determined with varying amounts of GST-R16A (F), PP1 binding consensus mutant form of GST-R16A (E) or GST (f) using 32 P-labeled myelin basic protein as substrate as described under Materials and Methods. Relative remaining activities were calculated taking PP1␤ activity without adding inhibitors as one unit.
PPP1R16A Signals Nuclear Translocation of the Receptor CAR 1119
at ASPET Journals on September 6, 2017 molpharm.aspetjournals.org induction of nuclear translocation seems to be correlated. Furthermore, R16A specifically interacts with PP1␤ and inhibits its activity, whereas active PP1␤ in liver cells is inhibitory for nuclear translocation of CAR. Although many questions remain unanswered at this point, R16A may provide a clue for understanding the signaling mechanism that can regulate the nuclear translocation and activation of CAR. In this mechanism, CAR might exist on the cell membrane before moving into the nucleus by drug activation. In fact, a recent report (Koike et al., 2005) found CAR exists on the cell membrane. At the cell membrane, a R16A dimer/oligomer, which is induced by an unidentified signal originated from the drug activation, and CAR may form a temporal complex while CAR is activated to translocate into the nucleus. Our FRET analysis has demonstrated the close interactions of CAR with R16A on the cell membrane, supporting the notion that formation of this temporal complex can occur in the liver cell. Coprecipitation of endogenous CAR and R16A from the detergent-soluble fraction of the cell membrane using their antibodies did not allow us to detect a complex of these two proteins. In addition to several experimental difficulties, such as low contents of these proteins in the membrane fractions and the qualities of the antibodies currently available to us, the possible temporal and weak nature of their interactions may have prevented us from detecting an endogenous CAR-R16A complex. In the CAR activation process in the complex, the PP1␤ activity modulation by R16A may be involved. CAR translocation caused by R16A over expression without PB treatment may be triggered by spontaneous dimer/oligomer formation of R16A on the liver cells membrane. Even partial R16A, which lacked a PP1 binding consensus (residues 304 -524), showed strong activity for CAR translocation (Fig. 6B) . Dimer/oligomer formed between this deletion mutant and the endogenous R16A in mouse liver may be contributing the activity we observed.
R16A was originally identified as a PP1␣ catalytic subunit interacting protein (Skinner and Saltiel, 2001 ) in yeast two hybrid screening and named MYPT3 based on the similarity with MYPT proteins. R16A consists of 524 amino acid residues, in which five Ankyrin repeats and a consensus PP1 binding site are located within the N-terminal 300 amino acid residues. The C-terminal region with 224 residues contains two possible Src homology 3 binding sites and a prenylation motif (CaaX). These structural features suggest that R16A could be a scaffold protein regulating protein-protein interactions as well as cellular signaling. Our results demonstrated membrane localization of this protein. Furthermore, deletion mutants that retain the CaaX motif were distributed on the membrane, but deletion mutants that lacked this motif were not (data not shown) suggesting that the CaaX motif is in fact farnesylated to localize the molecules on the cell membrane in liver. R16A shows a highly specific interaction with PP1␤, which is one of the three PP1 catalytic subunits in humans, PP1␣, PP1␤ (also called PP1␦), and PP1␥. These are extremely homologous proteins, with 88% amino acid identity between PP1␤ and PP1␣ and 87% between PP1␤ and PP1␥. Consistent with our results, similar specific interaction between R16A and PP1␤ has been reported quite recently using His-tagged R16A expressed in COS-7 cells (Yong et al., 2006) . In Drosophila melanogaster, orthologous proteins of mammalian R16A and PP1␤ specifically interact with each other (Vereshchagina et al., 2004) . From these facts, we postulated that PP1␤ might have effects on CAR nuclear translocation and NR1 reporter activation. Indeed, as shown in Fig. 4 , PP1␤ activity was inhibitory for the translocation and activation of the reporter. A recent report established that PKA phosphorylation of R16A could affect inhibitory activity for PP1␤ (Yong et al., 2006) . Upon PKA phosphorylation, R16A intermolecular interactions were significantly reduced, and it became an activator for PP1␤. Furthermore, suggested phosphorylation sites are localized in the region that is critical for dimerization (Ser340, Ser341, and Ser353 in human R16A). Thus, how PKA regulates R16A dimerization for PP1␤ activity modulation in PB induced CAR translocation and activation is an area for further study.
Collectively, R16A widens our insight into understanding the induction mechanism by xenobiotics and may lead us one step closer to the initial site of PB action. An increasing number of CAR activators such as phenytoin are now included with those displaying the same activation characteristics as PB (Jackson et al., 2004; Wang et al., 2004 ). The . PP1␤ inhibits nuclear translocation of CAR. A, CFP-hCAR was coexpressed in mouse liver with YFP-tagged PP1␤, its active site mutant PP1␤ H124A or YFP alone. Mice are treated with PB and liver sections were analyzed under microscope. Intracellular localization was categorized into three groups: nuclear localization (N), cytoplasmic localization (C), similar localization in both nucleus and cytoplasm (N ϭ C). Approximately 120 cells were randomly selected for each group to analyze the localizations. B, inhibition of PB induced NR1 reporter activities by coexpression of PP1␤ in mouse liver. NR1 luciferase reporter plasmid was coinjected into mice with PP1␤, its active site mutant (PP1␤H 124A ), or empty expression plasmids through tail vein. Luciferase activities in livers from PB or saline-treated mice were determined as under Materials and Methods. Bars indicate means with standard deviation from quadruplicate measurements.
other xenosensing nuclear receptor PXR has also been reported to translocate into the nucleus in response to an activator (Kawana et al., 2003; Squires et al., 2004) , and preliminary results suggested this receptor also interacts with R16A (data not shown). Because PXR and CAR are activated by numerous xenobiotics, including therapeutic drugs and environmental pollutants, affecting drug toxicity and drug-drug interactions (Honkakoski and Negishi, 2000; Xie and Evans, 2001; Willson and Kliewer, 2002; Honkakoski et al., 2003) , R16A may provide us with a novel candidate as target of the xenobiotics that can modulate the function of these receptors.
